OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Gastroenterology & Hepatology is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Regulating protease homeostasis in irritable bowel syndrome	696
Hybrid EASL Congress 2023	516
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity	478
Zolbetuximab treatment in metastatic gastric cancer	478
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection	460
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis	403
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology	388
Digestive Disease Week 2022	363
Mapping neuroimmune interactions in the gut	347
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	321
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed	318
2023 FDA approvals in gastroenterology and hepatology	315
Nomenclature of HBV core protein-targeting antivirals	304
Black–White disparities across the colorectal cancer care continuum in the USA	300
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis	286
Artificial intelligence and automation in endoscopy and surgery	275
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection	235
Leveraging diet to engineer the gut microbiome	220
Western lifestyle, metaflammation and the cell of origin of colon cancer	213
Hepatic IRF3 in glucose intolerance	205
Oral microbiome therapy efficacious for recurrent C. difficile infection	193
Wound healing in the colon	186
GWAS reveals variants for alcohol-related hepatocellular carcinoma	182
Decoding therapy resistance in liver tumours: a giant leap	181
A deep dive into the submerged ‘coeliac iceberg’	179

New understanding of hepatobiliary MRI	177
Lessons from incretin-based therapy in MASH and obesity	172
Metastatic pancreatic cancer and the liver	168
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract	167
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges	162
A crucial Fusobacterium nucleatum clade in colorectal cancer	157
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation	156
Bacteriophages and their potential for treatment of gastrointestinal diseases	155
The global burden of coeliac disease: opportunities and challenges	153
Inflammatory bowel disease in pregnancy and breastfeeding	147
Integrated systems approach to identify environmental factors in intestinal inflammation	144
Hepatocyte-derived biomarkers in alcohol-related cirrhosis	142
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases	138
Medical therapy of paediatric inflammatory bowel disease	128
Lanifibranor and NASH resolution	127
Implications of the evolving knowledge of the genetic architecture of MASLD	126
Estimating dietary intake from human stool DNA	124
Preventing the progression of cirrhosis to decompensation and death	121
Characterizing the genomic landscape of colorectal cancer	116
SSRIs and depression: role of gut–brain communication	113
Probiotics for preterms: sharing complex decision-making	108
HDCA ameliorates NAFLD in mice	108
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook	106
Metabolic diseases in the East Asian populations	106
Liver, ageing and disease	105
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management	105
Current and future colorectal cancer screening strategies	105
Human intestinal B cells in inflammatory diseases	105
The path to successful hepatitis C elimination in Spain	103
ECCO’24	100
Author Correction: Hepatic immune regulation and sex disparities	99
NAFLD prevalence in older patients with T2DM	98
Phase III results for first-line treatment for metastatic colorectal cancer	96
Microbiota and colorectal cancer — controlling for confounders challenges associations	95
Gut microbiome and autism spectrum disorder	94
Enteric nervous system transfers stress to the gut	93
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’	92
GLP1R agonists in NAFLD: a promising therapy on the horizon	92
Transforming the landscape of liver cancer detection and care	91
Artificial intelligence in liver cancer — new tools for research and patient management	88
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance	87
Hepatic glucose metabolism in the steatotic liver	86
Neutrophils as potential therapeutic targets in hepatocellular carcinoma	84
Foundations of gastrointestinal-based drug delivery and future developments	80
Hepatic inflammatory responses in liver fibrosis	79
Immunoregulatory role of enteric glia	78
SMART cancer risk prediction	78
Liver dialysis in ACLF	76
AI predicts pancreatic cancer risk	75
The gut microbiome in feast and famine	74

Elucidating the transmission landscape of the human microbiome	71
Gut bacteria go on record	71
Author Correction: Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel	70
Future direction of total neoadjuvant therapy for locally advanced rectal cancer	67
Nutrient sensing and small intestinal enteric neurons	66
A new era in obesity management	63
Hepatitis E virus: from innate sensing to adaptive immune responses	63
MASLD as a non-communicable disease	63
International collaborative research to improve gallbladder cancer prevention	57
Nifty new tools for microbiome treatment design	56
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice	53
Revisiting fibrosis in inflammatory bowel disease: the gut thickens	52
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests	51
Postbiotics — when simplification fails to clarify	50
Danger! P2Y14 receptor links cell death to liver fibrosis	49
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	49
Cathepsin S in liver fibrogenesis	48
Tirzepatide to treat obesity: phase III results	48
A novel pathomics signature for gastric cancer	46
Origin of CAFs in colorectal cancer	46
Bridging the gap: increasing MENA representation in MASLD clinical trials	45
Natural history of NAFLD: knowns and unknowns	45
Commensal fungi in intestinal health and disease	44
Cellular and molecular basis of proximal small intestine disorders	43
Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors	42
Antibiotic-perturbed microbiota and the role of probiotics	39
The steatotic liver disease burden paradox: unravelling the key role of alcohol	38
Therapeutic landscape and future direction of metastatic colorectal cancer	36
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer	36
Classifying compounds as prebiotics — scientific perspectives and recommendations	36
Telemedicine for hepatitis C virus treatment in opioid treatment programmes	35
Long-term normothermic liver perfusion	34
Author Correction: Improving IBD outcomes in the era of many treatment options	33
Justice, equity, diversity and inclusion in gastroenterology and hepatology	31
Alcohol-free and low-strength drinks: friend or foe?	31
Diet-driven microbiome restoration associated with cardiometabolic benefits	30
Public health policies to prevent alcohol-related liver disease	28
Author Correction: Current and future colorectal cancer screening strategies	28
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus	28
Hippo signalling in the liver: role in development, regeneration and disease	28
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease	27
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach	27
Equitable partnerships and the path to inclusive, innovative and impactful human microbiome research	26
Global epidemiology of cirrhosis — aetiology, trends and predictions	26
A Roadmap for the Human Gut Cell Atlas	26
Digestive Disease Week 2023	25
ECCO’25	25
New target and timing in PDAC immunotherapy?	25
Resmetirom safe for nonalcoholic fatty liver disease	25
Location, location, location — spatial insight into hepatic macrophage populations	25
Intermittent fasting for NASH and HCC in mice	23
Elafibranor in primary biliary cholangitis	23
Deciphering potential implications of dietary microplastics for human health	22
Envisioning how to advance the MASH field	22
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions	21
Gastrointestinal health and the environment: a bidirectional relationship	21
A resource for the food microbiome and its links with the human microbiome	21
Food inequity and insecurity and MASLD: burden, challenges, and interventions	21
Digestive Disease Week 2025	21
HCV direct-acting antiviral therapy adherence in people who inject drugs	20
Follow-up of SER-109 for recurrent C. difficile	20
Autocrine signalling discovery reveals potential therapeutic targets in NASH fibrosis	20
Human liver tissue in a mouse host	20
Amitriptyline as second-line treatment for IBS in primary care settings	20
Nanoparticles in NAFLD therapeutics	20
RNA vaccine induces long-lived anti-tumour T cells in pancreatic cancer	19
Lactylation and HCC progression	19
IL-17A-producing CD8+ T cells in pancreatic cancer	19
COVID-19 and liver disease: where are we now?	19
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology	18
Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology	18
Gastrointestinal post-acute COVID-19 syndrome	18
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease	17
Biologic agents for IBD come of age as host–microbe interactions emerge	16
Liver steatosis and fibrosis in China	16
Paving the way: the road to be taken for proper NAFLD health care	16
Mucus secretion from colonic goblet cells is regulated by autophagy and ER stress	16
Mapping the malignant transformation from polyps to CRC	16